Drug Type in vivo CAR-T therapy |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| B-cell lymphoma recurrent | Phase 1 | China | 30 Sep 2025 | |
| B-cell lymphoma refractory | Phase 1 | China | 30 Sep 2025 | |
| Neoplasms | Clinical | China | - |





